- There were around 47,300 new cases of prostate cancer in the UK in 2013, that’s 130 cases diagnosed every day.
- Prostate cancer is the second most common cancer in the UK (2013).
- Prostate cancer accounts for 13% of all new cases in the UK (2013).
- In males in the UK, prostate cancer is the most common cancer, with around 47,300 cases diagnosed in 2013.
- More than half (54%) of prostate cancer cases in the UK each year are diagnosed in males aged 70 and over (2011-2013).
- Since the late 1970s, prostate cancer incidence rates in males have more than doubled (155% increase) in Great Britain; this is linked with PSA testing.
- Over the last decade, prostate cancer incidence rates in males have increased by around a twentieth (5%) in the UK.
- Prostate cancer in England is less common in males living in the most deprived areas.
- In Europe, around 417,000 new cases of prostate cancer were estimated to have been diagnosed in 2012. The UK incidence rate is 17th highest in Europe.
- Worldwide, more than 1.11 million men were estimated to have been diagnosed with prostate cancer in 2012, with incidence rates varying across the world.
- 1 in 8 men will be diagnosed with prostate cancer during their lifetime.
Prostate cancer statistics
New cases of prostate cancer, 2013, UK
Deaths from prostate cancer, 2014, UK
Survive prostate cancer for 10 or more years, 2010-11, England and Wales
Preventable cases of prostate cancer are not known as it is not clearly linked to any preventable risk factors
- There were around 11,300 prostate cancer deaths in the UK in 2014, that’s 31 deaths every day.
- Prostate cancer is the fourth most common cause of cancer death in the UK (2014).
- Prostate cancer accounts for 13% of all cancer deaths in males in the UK (2014).
- In males in the UK, prostate cancer is the second most common cause of cancer death, with around 11,300 deaths in 2014.
- Almost three quarters of prostate cancer deaths occur in men aged 75 and over.
- Prostate cancer death rates peaked in the early 1990s and have since fallen by around a fifth.
- Prostate cancer deaths in England are not associated with deprivation
- In Europe, around 92,300 men were estimated to have died from prostate cancer in 2012. The UK mortality rate is 15th highest in Europe.
- Worldwide, more than 307,000 men were estimated to have died from prostate cancer in 2012, with mortality rates varying across the world.
- More than 8 in 10 (84%) men diagnosed with prostate cancer in England and Wales survive their disease for ten years or more (2010-2011).
- Almost 9 in 10 (85%) men diagnosed with prostate cancer in England and Wales survive their disease for five years or more (2010-2011).
- Almost 95% (94%) of men diagnosed with prostate cancer in England and Wales survive their disease for one year or more (2010-2011).
- Prostate cancer survival in England is higher for men diagnosed aged 60-69 years old, probably because of PSA testing detecting latent, earlier, slow-growing cancers (2009-2013).
- Almost 95% of men in England diagnosed with prostate cancer aged 50-59 or 60-69 survive their disease for five years or more, compared with two thirds of men diagnosed aged 80 and over (2009-2013).
- Prostate cancer survival is improving and has tripled in the last 40 years in the UK, probably partly because of PSA testing detecting latent, earlier, slow-growing cancers.
- In the 1970s, a quarter of men diagnosed with prostate cancer survived their disease beyond ten years, now it's more than 8 in 10.
- When diagnosed at its earliest stage, all men with prostate cancer will survive their disease for five years or more, compared with less than a third of men when diagnosed at the latest stage.
- Prostate cancer is not clearly linked to any preventable risk factors.
- A man’s risk of developing prostate cancer depends on many factors, including age,genetics, and possibly exposure to risk factors.
- No modifiable factors have been conclusively linked with prostate cancer risk, though many factors have been studied. Use of PSA testing often makes interpretation of evidence difficult.
- Some factors may relate to higher prostate cancer risk, including certain occupational exposures, ionising radiation, and certain medical conditions, but evidence is unclear.
- Some foods and supplements may relate to lower prostate cancer risk, but evidence is unclear.
- 'Two-week wait’ is the most common route to diagnosis of prostate cancer.
- GP referral is the route with the highest proportion of cases diagnosed at an early stage, for prostate cancer.
- ‘Two-week wait’ standards are met by all countries, ‘31-day wait’ and ‘62-day wait’ are not met by any country for urological cancers.
- Almost a tenth of prostate cancer patients receive major surgical resection as part of their cancer treatment.
- Almost 9 in 10 patients had a ‘very good’ or ‘excellent’ patient experience.
- More than 8 in 10 patients are given the name of their Clinical Nurse Specialist.
The latest statistics available for prostate cancer in the UK are; incidence 2013, mortality 2014 and survival 2010-2011 (all ages combined) and 2009-2013 (by age).
European Age-Standardised Rates were calculated using the 1976 European Standard Population (ESP) unless otherwise stated as calculated with ESP2013. ASRs calculated with ESP2013 are not comparable with ASRs calculated with ESP1976.
Lifetime risk estimates were calculated using incidence, mortality, population and all-cause mortality data for 2012.
Survival statistics give an overall picture of survival and (unless otherwise stated) include all adults (15-99) diagnosed, at all ages,
Stage at diagnosis data is not yet routinely available for the UK due to inconsistencies in the collecting and recording of staging data in the past.
Routes to diagnosis statistics were calculated from cases of cancer registered in England which were diagnosed in 2012-2013. Staging proportions only include patients with a known stage (cases with an unknown stage at diagnosis are not included in the denominator).
Cancer waiting times statistics are for patients who entered the health care system within financial year 2014-15. Prostate cancer is part of the group 'Urological cancer' for cancer waiting times data. Codes vary per country but broadly include: penis, prostate, testis, other and unspecified male genital organs, kidney, renal pelvis, ureter, bladder, other and unspecified urinary organs, secondary cancers of kidney, renal pelvis, bladder and other unspecified urinary organs.
Cancer surgical resection rates data is for patients diagnosed in England between 2006 and 2010.
Patient Experience data is for adult patients in England with a primary diagnosis of cancer, who were in active treatment between September and November 2013 and who completed a survey in 2014.
Deprivation gradient statistics were calculated using incidence data for three time periods: 1996-2000, 2001-2005 and 2006-2010 and for mortality for two time periods: 2002-2006 and 2007-2011. The 1997-2001 mortality data were only used for the all cancers combined group as this time period includes the change in coding from ICD-9 to ICD-10. The deprivation quintiles were calculated using the Income domain scores from the Index of Multiple Deprivation (IMD) from the following years: 2004, 2007 and 2010. Full details on the data and methodology can be found in the Cancer by Deprivation in England NCIN report.
You are welcome to reuse this Cancer Research UK statistics content for your own work.
Credit us as authors by referencing Cancer Research UK as the primary source. Suggested styles are:
Web content: Cancer Research UK, full URL of the page, Accessed [month] [year].
Publications: Cancer Research UK ([year of publication]), Name of publication, Cancer Research UK.